Source Targeted Oncology JAK inhibition continues to drive progress in myelofibrosis treatment as fedratinib (Inrebic) now joins ruxolitinib (Jakafi) in the treatment landscape for myelofibrosis. Since its FDA approval in August 2019, fedratinib has become both an additional treatment and a second-line option for patients who respond poorly to ruxolitinib. The approval of fedratinib was
The EU needs an ambitious and coherent agenda for the 2019-2024 legislative term to boost the resilience, equitability and sustainability of Europe’s healthcare systems. This report, based on a Science|Business expert roundtable, sets out recommendations for such an agenda. When it comes to healthcare, Europe has strong foundations on which to build. It already has
Source https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(19)30339-X?elqTrackId=39785ec7f12f4ed79ff115249bc871f5&elq=81c0af21c850457daca48d5be457f158&elqaid=26028&elqat=1&elqCampaignId=10599 Invariant natural killer T (iNKT) cells are potent immune cells for targeting cancer; however, their clinical application has been hindered by their low numbers in cancer patients. Here, we developed a proof-of-concept for hematopoietic stem cell-engineered iNKT (HSC-iNKT) cell therapy with the potential to provide therapeutic levels of iNKT cells for a patient’s
The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas. ADP-A2M4 (Adaptimmune) is an autologous, genetically modified SPEAR T-cell therapy that targets the MAGE-A4 antigen on the surface of cancer cells. Certain soft tissue sarcomas express MAGE-A4 at high levels and
Source September 5th, 2019 by Dr. Francis Collins Tumor cells thrive by exploiting the willingness of normal cells in their neighborhood to act as accomplices. One of their sneakier stunts involves tricking the body into helping them form new blood vessels. This growth-enabling process of sprouting new blood vessels, called tumor angiogenesis, remains a vital area of
Two-pronged approach stymies AML escape plan, could have applications to many cancers. Scientists from the National Institutes of Health and Cincinnati Children’s Hospital Medical Center have devised a potential treatment against a common type of leukemia that could have implications for many other types of cancer. The new approach takes aim at a way that
New research reveals a new role for the enzyme telomerase, which scientists thought was turned off in most normal adult cells, except in cancerous tumors where it promotes unlimited cell division. The researchers discovered that as normal, healthy adult cells approach cell-death, they produce a burst of telomerase that prevents malignancies and softens the final
Immunotherapy can be effective in treating certain types of pediatric blood cancers, but researchers are still exploring how this type of treatment could work for pediatric solid tumors. In clinical trials, scientists are combining immunotherapy agents in an effort to jump-start the immune system against pediatric solid tumors. Source DANA-FARBER Cancer Institute New treatments that
Sonic Hedgehog Medulloblastoma Can Turn into a Stubborn Killer of Children One of the most common brain cancers in children, Sonic Hedgehog (SHH) medulloblastoma, also is one of the more survivable for most kids. Unfortunately, for a subset of patients the cancer resists treatment and relapses with a vengeance to then turn deadly. Researchers at Cincinnati
The Personalized Medicine Coalition (PMC) released its annual “Personalized Medicine At FDA: A Progress & Outlook Report” (Report) that monitors current successes and challenges in bringing personalized therapies to market. Notable Developments for 2018 Several milestones were noted for 2018 – ranging from new drug approvals to direct-to-consumer genetic testing. 1. A record number of
